



## **Molecular Partners Publishes Audited Financial Results for 2020 and Annual Report 2020**

February 26, 2021

Zurich-Schlieren, Switzerland, February 26, 2021. [Molecular Partners AG](#) (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today published its audited Financial Results for 2020 and the company's 2020 Annual Report.

The [Audited Financial Results for 2020 and the company's 2020 Annual Report](#) are available on the investors section of the [company's website](#).

### **About Molecular Partners AG**

Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

[www.molecularpartners.com](http://www.molecularpartners.com); Follow the Company on Twitter at [@MolecularPrtnrs](#).

### **For further details, please contact:**

Investors:

Seth Lewis

[seth.lewis@molecularpartners.com](mailto:seth.lewis@molecularpartners.com)

Tel: +1 781 420 2361

Media:

Shai Biran, Ph.D.

[shai.biran@molecularpartners.com](mailto:shai.biran@molecularpartners.com)

Tel: +1 978 254 6286

Stefan Riley

[stefan@tenbridgecommunications.com](mailto:stefan@tenbridgecommunications.com)

Tel: +1 617 461 2442

Thomas Schneckeburger, IR & European Media

[thomas.schneckeburger@molecularpartners.com](mailto:thomas.schneckeburger@molecularpartners.com)

Tel: +41 79 407 9952